Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Libanati, C.
Right arrow Articles by Baylink, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Libanati, C.
Right arrow Articles by Baylink, D.

Chest, Vol 102, 1426-1435, Copyright © 1992 by American College of Chest Physicians

ARTICLES

Prevention and treatment of glucocorticoid-induced osteoporosis. A pathogenetic perspective

CR Libanati and DJ Baylink
Department of Medicine, Loma Linda University, Calif.

Since the discovery of cortisol and the synthesis of related compounds, these potent pharmacologic agents have been progressively more widely utilized in allergic, pulmonary, and rheumatologic conditions. Organ transplantation represents a new group of patients added to the already large pool of subjects receiving glucocorticoids. However, glucocorticoids cause major side effects involving several organ systems, including the cardiovascular, endocrine, gastrointestinal, ophthalmologic, and musculoskeletal systems. Among the most dramatic side effects is the development of glucocorticoid-induced osteoporosis. Glucocorticoid use in the treatment of chronic obstructive pulmonary disease accounts for the majority of male patients with osteoporosis seen in our mineral metabolism clinic. This article focuses on glucocorticoid-induced osteoporosis in the adult with an emphasis on the clinical aspects of this condition. It is intended not as an extensive review on the subject but as a practical guide to help clinicians prevent and treat this condition in adult patients.


This article has been cited by other articles:


Home page
 J. Exp. Biol.Home page
S. W. Donahue, M. R. Vaughan, L. M. Demers, and H. J. Donahue
Bone formation is not impaired by hibernation (disuse) in black bears Ursus americanus
J. Exp. Biol., December 1, 2003; 206(23): 4233 - 4239.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
R. A. Adler and M. C. Hochberg
Suggested Guidelines for Evaluation and Treatment of Glucocorticoid-Induced Osteoporosis for the Department of Veterans Affairs
Arch Intern Med, November 24, 2003; 163(21): 2619 - 2624.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American College of Chest Physicians.